Macrogenics Inc Revenue Growth Rates (MGNX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Macrogenics Inc   (NASDAQ: MGNX)
 

MGNX's Revenue Growth by Quarter and Year

Macrogenics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MGNX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 32.83
1st Quarter March 20.78
FY 53.61

MGNXs Annual Revenue
Macrogenics Inc 's Revenue in the fiscal year 2025 $ 149.50 millions
Macrogenics Inc 's Revenue in the fiscal year 2024 $ 149.96 millions
Macrogenics Inc 's Revenue in the fiscal year 2023 $ 58.75 millions
Macrogenics Inc 's Revenue in the fiscal year 2022 $ 151.94 millions
Macrogenics Inc 's Revenue in the fiscal year 2021 $ 77.45 millions




MGNX Revenue second quarter 2026 Y/Y Growth Comment
Macrogenics Inc achieved in the second quarter 2026, above Company average Revenue surge of 377.9% year on year, to $ 32.83 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 93 other companies have achieved higher Revenue growth. While Macrogenics Inc ' s Revenue doubling of 377.9% ranks overall at the positon no. 1749 in the second quarter 2026.


MGNX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 113.07 % 80.5 % -85.34 %
3rd Quarter September - -34.21 % 964.52 % -75.08 %
2nd Quarter June 377.9 % -36.39 % -17.81 % -49.48 %
1st Quarter March 57.54 % 44.95 % -62.86 % 120.72 %
FY   - -10.56 % 155.21 % -

Financial Statements
Macrogenics Inc 's second quarter 2026 Revenue $ 32.83 millions MGNX's Income Statement
Macrogenics Inc 's second quarter 2025 Revenue $ 6.87 millions Quarterly MGNX's Income Statement


MGNX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -43.4 % -82.52 % 3.08 %
3rd Quarter September - 960.26 % 925.09 % -20.85 %
2nd Quarter June 58 % -47.92 % 18.68 % -46.37 %
1st Quarter March -49.6 % -31.83 % -15.11 % -66.48 %
FY (Year on Year)   - -10.56 % 155.21 % -


Back to MGNX Growth rate Comparisons >> Back to MGNX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #94
Healthcare Sector #276
Overall #1749

Revenue Y/Y Growth Statistics
High Average Low
1774.99 % 86.07 % -88.95 %
(Sep 30 2018)   (Sep 30 2017)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #94
Healthcare Sector #276
Overall #1749
Revenue Y/Y Growth Statistics
High Average Low
1774.99 % 86.07 % -88.95 %
(Sep 30 2018)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Macrogenics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
9061.7 % 252.5 % -96.92 %
(Dec 31 2017)  


MGNX's II. Quarter Q/Q Revenue Comment
Macrogenics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 58% quarter on quarter, to $ 32.83 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the -47.92% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Macrogenics Inc 's Revenue growth quarter on quarter, overall rank is 212.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #212
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #212
Revenue Q/Q Growth Statistics
High Average Low
9061.7 % 252.5 % -96.92 %
(Dec 31 2017)  


MGNX's II. Quarter Q/Q Revenue Comment
Macrogenics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 58% quarter on quarter, to $ 32.83 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -47.92% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Macrogenics Inc 's Revenue growth quarter on quarter, overall rank is 212.


Macrogenics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 167.67 $ 141.71 $ 134.13 $ 112.25 $ 150.12
Y / Y Revenue Growth (TTM) 11.69 % -8.01 % -10.56 % -20.57 % 265.99 %
Year on Year Revenue Growth Overall Ranking # 70 # 60 # 38 # 564 # 2847
Seqeuential Revenue Change (TTM) 18.32 % 5.65 % 19.49 % -25.23 % -2.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 2867 # 1965 # 1230 # 32 # 2206


Cumulative Revenue growth Comment
Although Macrogenics Inc 's Annual Revenue growth year on year were below company's average 84.93% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 11.69% year on year, from -8.01% in Mar 31 2026.

Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 60 to 70.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 128
Healthcare Sector # 22
Overall # 70

Revenue TTM Y/Y Growth Statistics
High Average Low
1774.99 %
 84.93 %
-88.95 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 128
Sector # 403
S&P 500 # 2867
Cumulative Revenue growth Comment
Although Macrogenics Inc 's Annual Revenue growth year on year were below company's average 84.93% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 11.69% year on year, from -8.01% in Mar 31 2026.

Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 60 to 70.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 128
Healthcare Sector # 22
Overall # 70

Revenue TTM Y/Y Growth Statistics
High Average Low
1774.99 %
84.93 %
-88.95 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 128
Sector # 403
S&P 500 # 2867




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MGNX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Nuvation Bio Inc 644.35%$ 644.350 millions
Tonix Pharmaceuticals Holding Corp 577.88%$ 577.878 millions
Allogene Therapeutics Inc 567.50%$ 567.500 millions
Brightspring Health Services Inc 555.52%$ 555.518 millions
Bullfrog Ai Holdings Inc 547.64%$ 547.638 millions
Northwest Biotherapeutics Inc516.03%$ 516.031 millions
Vistagen Therapeutics Inc 504.92%$ 504.918 millions
Kymera Therapeutics Inc 466.40%$ 466.399 millions
Surrozen Inc 408.65%$ 408.647 millions
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions


About Macrogenics Inc Revenue Growth Rates (MGNX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Macrogenics Inc (CIK 1125345).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001125345-26-000056
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Macrogenics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.